Genmab A (GMAB) Total Debt (2022 - 2026)

Genmab A (GMAB) has reported Total Debt for 5 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Debt changed N/A year-over-year to $5.1 billion; the trailing twelve-month figure through Jun 2026 stood at $5.1 billion (changed N/A YoY), and the FY2025 full-year result was $5.3 billion, up 5695.9% from the prior year.
• Total Debt rose to $5.1 billion in Q2 2026 per GMAB's latest filing, from $4.9 billion in the prior quarter.
• Across five years, Total Debt topped out at $5.3 billion in Q4 2025 and bottomed at $74.6 million in Q4 2022.
• Historically, Total Debt has averaged $2.6 billion across 5 years, with a median of $2.5 billion in 2026.
• The sharpest annual moves came in 2024 and 2025: Total Debt gained 1.43% in 2024, then soared 5695.9% in 2025.
• Over 5 years, Total Debt stood at $74.6 million in 2022, then rose by 20.33% to $89.7 million in 2023, then gained by 1.43% to $91.0 million in 2024, then jumped by 5695.9% to $5.3 billion in 2025, then retreated by 2.64% to $5.1 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $5.1 billion, $4.9 billion, and $5.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.